Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 38
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth

  • Bach Griera, Marc|||0000-0001-9845-7225
  • Hernández, Alba|||0000-0001-6938-1233
  • Julián, Esther|||0000-0002-6558-3978
Bladder cancer (BC) is a highly recurrent and invasive malignancy, with Mycobacterium bovis BCG serving as the primary immunotherapy, particularly for non-muscle-invasive bladder cancer (NMIBC). However, the mechanisms underlying BCG's antitumor effects and the potential of non-tuberculous mycobacteria like Mycobacterium brumae remain unclear. This study investigates the antitumor effects of M. bovis BCG and M. brumae on BC cell migration, invasion, and anchorage-independent growth. BC cell lines representing different stages of tumor differentiation were treated with either M. bovis BCG or M. brumae. Cell migration was assessed through wound healing and transwell assays, invasiveness by transwell invasion assays, MMP-9 production by gelatin zymography, and anchorage-independent growth via soft agar colony formation. Both mycobacteria inhibited individual cell migration across all BC lines, while collective migration was only reduced in intermediate-grade cells. Both treatments also reduced invasiveness, associated with decreased MMP-9 production. Furthermore, M. brumae inhibited anchorage-independent growth across all BC lines, while M. bovis BCG had a more selective effect, primarily inhibiting growth in high-grade cells. In conclusion, both mycobacteria reduce migration, invasion, and anchorage-independent growth of BC cells, with their effectiveness varying by species and tumor differentiation grade.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Surpassing protein specificity in biomimetics of bacterial amyloids

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
In nature, nontoxic protein amyloids serve as dynamic, protein-specific depots, exemplified by both bacterial inclusion bodies and secretory granules from the endocrine system. Inspired by these systems, chemically defined and regulatory-compliant artificial protein microgranules have been developed for clinical applications as endocrine-like protein repositories. This has been achieved by exploiting the reversible coordination between histidine residues and divalent cations such as Zn, that promotes protein-protein interactions. While stereospecificity is a main architectonic feature of natural amyloids, the potential for synthetic approaches to create hybrid protein materials remains unexplored. Such materials could enable the occurrence and synchronized local application of diverse proteins in predefined molar ratios, for coupled enzymatic reactions or delivery of synergistically acting polypeptides. Here, we report on the fabrication of artificial protein granules with amyloidal architecture formed by combining two structurally distinct polypeptides. Specifically, we tested co-aggregation of the pairs GFP/IRFP and GFP/β-galactosidase. The formation of hybrid microparticles was confirmed through FRET and complementary methodologies, demonstrating that the His-Zn clustering technology does not require sequential or structural homologies between aggregating polypeptides. This approach opens new avenues for the development of functional depots that capitalize on synergistic protein functionalities, paving the way for next-generation functional materials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Citrate-Assisted Regulation of Protein Stability and Secretability from Synthetic Amyloids

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Chellou-Bakkali, Sara|||0009-0007-1643-4558
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
The mammalian endocrine system uses functional amyloids as dynamic depots to store and release protein hormones into the bloodstream. Such depots, acting as secretory granules within the microscale, are formed in specialized cells by the coordination between the ionic, divalent form of zinc (Zn2+) and the imidazole ring from accessible His residues. The reversibility of such cross-linking events allows for the release of monomeric or oligomeric forms of the functional protein for biological activity. In vitro, and mimicking such a natural coordination process, synthetic amyloidal granules with secretory properties can be fabricated using selected therapeutic proteins as building blocks. Then, these microparticles act as delivery systems for endocrine-like, sustained protein release, with proven applicability in vaccinology, cancer therapy, regenerative medicine, and as antimicrobial agents. While the temporal profile in which the protein is leaked from the material might be highly relevant to clinically oriented applications, the fine control of such parameters remains unclear. We have explored here how the kinetics of protein release can be regulated by intervening in the storage formulation of the granules, through the concentration of citrate not only as a buffer component and protein stabilizer but also as a chelating agent. The citrate-assisted, time-prolonged regulatable release of proteins, in their functional form, opens a spectrum of possibilities to adjust the preparation of synthetic secretory granules to specific clinical needs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Trans-Mediated, Cis-Inhibited Paradoxal Activity of Clostridium perfringens Enterotoxin (c-CPE) in Modulating Epithelial Permeability

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Di Somma, Angela|||0000-0003-4916-7875
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
In the context of transdermal delivery, favoring the drug permeability of epithelia through convenient formulations would open new opportunities for local versus systemic drug delivery, envisaging higher patient comfort and an enhanced therapeutic effect. Ligands of tight junctions are interesting agents that enhance epithelial permeability by relaxing the protein complexes that form them. The C-terminal domain of Clostridium perfringens enterotoxin (c-CPE), which binds claudins, one of the tight junction (TJ) components, has been explored here as a functional domain in modular recombinant proteins, to evaluate its ability to self-promote its paracellular epithelial passage in a Caco-2 cell monolayer model. c-CPE-containing fusion proteins bind cells in the absence of internalization and cytotoxicity and support the passage, in trans, of other fusion proteins devoid of c-CPE. However, c-CPE-carrying proteins fail to cross the epithelia by themselves, probably because their affinity for TJs immobilizes them in the intercellular space. Therefore, while recombinant c-CPE versions have been here confirmed as convenient epithelial-permeabilizing agents, a paradoxical behavior has been observed where this effect is only successful when applied in trans, specifically on entities that lack c-CPE. Then, c-CPE itself inhibits the paracellular mobility of carrier molecules, not being suited as a self-driver (in c-CPE-drug complexes) for drug delivery through epithelia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi|||0000-0001-5750-550X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez-Matínez, Merce
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Villaverde, Antonio|||0000-0002-2615-4521
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An acyl-homoserine lactone acylase found in Stenotrophomonas maltophilia exhibits both quorum quenching activity and the ability to degrade penicillin antibiotics

  • Bravo Bravo, Marc|||0000-0002-3173-2242
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Coves, Xavier|||0000-0002-8970-8907
  • García-Navarro, Andrea
  • Márquez-Martínez, Merce|||0000-0003-2157-5850
  • Gómez, Andromeda-Celeste|||0000-0002-0075-6903
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Gibert, Isidre|||0000-0003-1442-2258
  • Yero, Daniel|||0000-0002-6234-4082
Stenotrophomonas maltophilia are opportunistic, multi-drug-resistant Gram-negative pathogens increasingly prevalent in clinical settings. Quorum sensing (QS) systems play a crucial role in their pathogenesis, coordinating bacterial populations and enabling interactions within polymicrobial communities. While not the primary QS mechanism in S. maltophilia, these bacteria can respond to acyl-homoserine lactone (AHL)-type autoinducers. Some isolates exhibit AHL-quorum quenching activity, though the responsible components remain unidentified. Homology searches in S. maltophilia K279a revealed a protein with the locus tag SMLT_RS07305 (old locus tag Smlt1522), annotated as a putative penicillin acylase 2 precursor. Sequence and structural analyses classify this protein within the bacterial AHL-acylase group B, characterized by a heterodimeric structure consisting of α- and β-subunits connected by a spacer polypeptide. We experimentally confirmed the dual activity of Smlt1522 as an AHL-acylase and a penicillin acylase. This protein degrades AHLs with varying acyl chains and hydrolyses penicillin antibiotics in vitro, in vivo, and as an heterologously expressed product. Its physiological role includes the modulation of beta-lactam resistance, biofilm formation and bacterial fitness under specific conditions. Evolutionary analysis suggests structural and functional conservation, pointing to its potential role in the adaptation of S. maltophilia to diverse and competitive environments.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Targeting the chemokine receptor CXCR4 for cancer therapies

  • Rueda, Ariana|||0000-0001-7588-9279
  • Serna, Naroa|||0000-0001-5682-8198
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The C-X-C chemokine receptor type 4 (CXCR4) has emerged as a key molecular biomarker for cancer therapies due to its critical role in tumor progression and metastases by displaying a stem cells phenotype. Its overexpression has been observed in more than 20 types of cancers, including solid tumors and hematological malignancies, and it is often associated with tumor aggressiveness and poor prognosis. Being initially recognized as a co-receptor involved in HIV infection, numerous CXCR4-targeting ligands and antagonists, including small molecules, peptides and biologics have been identified over the past decades. While only few of them have been used in the context of cancer therapies, recent biotechnological advancements using CXCR4 as a molecular target are showing significant potential to revolutionize future cancer therapies. Therefore, this review highlights the biotechnological innovations developed for cancer therapy and diagnosis by targeting the chemokine receptor CXCR4. It also discusses future perspectives on emerging therapeutic strategies, ranging from the use of small molecule inhibitors that block receptor signaling to cutting-edge nanocarriers designed for the targeted delivery of innovative drugs and proteins into cancer stem cells, aiming at cell-selective precision nanomedicines.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Self-disintegrating protein-leaking microparticles for topical protein delivery

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Martínez-Cuentra, Genís Josep
  • Contreras, Estefanía|||0000-0002-8645-2790
  • Di Somma, Angela|||0000-0003-4916-7875
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Advanced drug delivery systems, if engineered to enhance drug stability and extend its kinetic bioavailability, are expected to expand the spectrum of local therapeutic approaches for dermatological conditions. In this context, the objective of this study was to explore whether artificial secretory granules, namely nontoxic, microscale granular Zn-assisted protein depots that leak the forming protein in a time-prolonged way, could be suited as functional agents in topical delivery. A model, recombinant form of the human fibroblast growth factor 2 (FGF-2), formulated as secretory granules, promoted efficient tissue repair and wound healing in a rat skin injury model faster than the natural repair process. The kinetic and histological analysis of FGF-2-treated wounds revealed that the package of the protein as secretory granules improves skin regeneration over the soluble version, and that it conduces to a more ordered construction of the extracellular matrix with limited risk of fibrosis. On the other hand, the addition of a claudin-binding peptide (c-CPE) as a fused protein segment slightly delays wound healing but offers functional and histological particularities that modulate the skin regeneration process. Altogether, the data presented here validates this endocrine-like protein drug delivery from synthetic disintegrating protein depots as a powerful and versatile platform for topical application in dermatological disorders.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic platform allows for prolonged tumor uptake of a tumor targeting protein

  • Álamo, Patricia|||0000-0003-0510-5701
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
Endocrine-like dynamic protein depots can be fabricated in vitro through the coordination of divalent zinc ions (Zn) with solvent-exposed histidine residues on functional proteins, leading to their controlled aggregation. The resulting microparticles, under physiological conditions, undergo progressive disintegration due to spontaneous Zn dilution, enabling a time-sustained release of the protein components. These chemically pure protein-based materials represent promising drug delivery platforms, with demonstrated efficacy in oncology, vaccinology, tissue regeneration, and antibacterial therapies. To enable systemic delivery of the embedded protein, alternative administration routes are potentially suited, but their effectiveness in terms of biodistribution and accumulation in target tissues remains unexplored. Using a CXCR4 cancer mouse model, we investigated the tumor targeting and permanence of a self-assembling, CXCR4-binding fluorescent protein administered in the form of secretory granules via subcutaneous, intramuscular, or intraperitoneal injection. Our data reveal that subcutaneous administration supports prolonged protein retention at the injection site, its release within the local draining lymphatic vessels, extended circulation time, and significantly higher tumor accumulation 10 days post-injection. Compared to intramuscular and intraperitoneal routes, the subcutaneous pathway presents clear advantages, potentially allowing reduced dosing frequency in protein-based therapies aimed at maintaining steady systemic and target tissue levels.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates

  • Rueda, Ariana|||0000-0001-7588-9279
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Aviñó, Ana|||0000-0003-3047-738X
  • Fabrega, Carme|||0000-0003-3816-7634
  • Eritja, Ramon|||0000-0001-5383-9334
  • Paez, David|||0000-0002-5596-6588
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Precision targeting is a hot topic in cancer nanomedicine, as conventional chemotherapies cause systemic toxicities, creating an urgent need for more selective treatments. Although antibody-drug conjugates (ADCs) are the current gold standard in targeted therapy, their clinical performance remains limited. As an alternative, we previously developed a multivalent protein nanocarrier (T22-GFP-H6) displaying the CXCR4-targeting peptide T22, which offers super-selective tumor accumulation driven by CXCR4 overexpression. This innovative nanovehicle showed favorable biodistribution for targeted delivery of antitumor drugs, including monomethyl auristatin E (MMAE), in a first-generation stochastic nanoconjugate format. However, unlike ADCs, where conjugation strategy is known to influence pharmacokinetics and efficacy, these parameters remain largely unexplored in non-antibody multivalent nanocarriers. Here, we evaluated the impact of precise payload accommodation using two site-specific strategies that attach a single MMAE molecule at distinct structural sites, and we compared them with first-generation nanoconjugates. The conjugation strategy substantially affected the biodistribution and antitumor efficacy, with a solvent-exposed cysteine-conjugation distal to the targeting ligand proving most effective. At equimolar nanocarrier dosing, this construct achieved tumor control similar to the stochastic conjugate in a disseminated hematologic malignancy despite an approximately 4-fold lower MMAE load (drug-to-protein ratio, DPR = 1 vs DPR ≈ 4). Moreover, at equimolar MMAE dosing, it clearly outperformed both the stochastic conjugate and the alternative site-directed design. These findings align with trends in advanced ADCs and provide practical design rules for rational, site-specific conjugation in next-generation protein-based nanomedicines aimed at enabling dose-sparing in oncology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecularly Imprinted Polymers as Biomimetic Test Zones in Paper-Based Nucleic Acid Assays-Comparing Vertical and Lateral Flow Formats

  • Marfà, Jennifer|||0000-0001-5321-3841
  • Valle, Anaixis del|||0000-0001-5587-9081
  • Taboada Sotomayor, Maria Del Pilar|||0000-0002-6173-7888
  • Pividori, María Isabel|||0000-0002-5266-7873
The development of rapid and sensitive point-of-care nucleic acid tests benefits from robust synthetic recognition elements. Here, a biotin-specific molecularly imprinted polymer (MIP) was synthesized using an optimized protocol and integrated as a biomimetic test zone into two paper-based formats: nucleic acid vertical flow (NAVF) and nucleic acid lateral flow (NALF). Both platforms were evaluated for the detection of double-tagged PCR amplicons from Escherichia coli. NAVF enabled a 3 min visual readout with an LOD of 1.00 × 10-2 ng mL-1. NALF provided a total assay time of <15 min and achieved a visual LOD of 3.17 × 10-2 ng mL-1. Overall, the results demonstrate the versatility of biotin-MIPs as stable synthetic receptors for rapid, low-cost paper-based nucleic acid assays, with NAVF prioritizing speed and design flexibility and NALF prioritizing higher analytical sensitivity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The biological activity of therapeutic proteins, upon intracellular delivery, is dramatically minimized by lysosomal proteolytic digestion. This is a limitation when developing cell-targeted pharmaceuticals that penetrate target cells via receptor recognition and endosomal engulfment. Since proteins benefit from functional and conformational versatility, editable by genetic engineering, endosomolytic protein domains are often fused to the functional polypeptide to promote their cytosolic delivery, aiming at minimizing proteolysis in mature lysosomes. This straightforward strategy has, however, rendered irregular results, linked to the fusogenic nature of most of the tested domains. Alternatively, proteolysis of protein drugs might be controlled by bypassing the lysosomal route, forcing an unconventional traffic of the uptaken protein material to be secreted from the endoplasmic reticulum (ER). This possibility, used in nature by several plant and microbial proteins, has been evaluated here by functionalizing a protein-only antitumoral drug, based on a cell-targeted diphtheria toxin, with a C-terminal KDEL motif. Thus, if KDEL were able to reprogram the intracellular trafficking, KDEL-tagged cell delivered proteins would be expected to avoid the lysosomal degradation, resulting in enhanced stability and activity. The obtained results validate this hypothesis and point out KDEL as a promising functional agent in cell-targeted protein drugs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Escribano-Ferrer, Elvira|||0000-0001-7837-9506
  • Huaca, Vanesa
  • Miranda-Tovar, Eva
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
The effective dermal delivery of functional proteins could substantially improve therapeutic options for common skin disorders, in which current lipid-based or invasive strategies face efficacy and safety limitations. We report a biomimetic protein depot platform based on granular, nontoxic amyloids generated through Zn-mediated coordination of hexahistidine-tagged proteins. Functionalization of these materials with either the cell-penetrating peptide R9 or the tight junction modulator c-CPE, the C-terminal region of the Clostridium perfringens enterotoxin, enabled a systematic evaluation of transdermal penetration in mouse models. Whereas plain and R9-functionalized granules showed restricted permeation, c-CPE-functionalized granules achieved consistent distribution through the dermis into the hypodermal layers. These findings establish self-assembled protein amyloids as a promising and adaptable class of biomaterials for dermal protein delivery. Also, the ability of c-CPE to enhance permeability without auxiliary adjuvants, lipids, or invasive methods highlights the translational potential of this system for clinically applicable, noninvasive management of cutaneous conditions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

GFP-like protein scaffolds for antigen grafting, Soluble and stable neoantigen display in mammalian-compatible platforms

  • Parladé, Eloi|||0000-0001-5750-550X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Chellou-Bakkali, Sara|||0009-0007-1643-4558
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Subunit vaccines are often limited by poor solubility and structural instability, affecting their ability to induce strong immune responses. Scaffold-based antigen display offers a promising solution, but translating designs into stable, scalable proteins remains challenging. Here, we present a pipeline for selecting and inserting tumor-derived peptide sequences into β-barrel protein frameworks, using both GFP and the structurally similar G2 domain of the mouse nidogen. We validate the ASP173 loop in GFP as an effective insertion site, accommodating a double-peptide construct, as well as two distinct single peptides, without compromising folding or fluorescence. We further show that this design logic extends to the mouse nidogen G2 domain, which we employ as a host-native scaffold to carry the inserted epitope. The resulting constructs retain structural integrity and thermal stability, supporting their use in preclinical models and facilitating future applications in human health. This work establishes a modular, mammalian-compatible platform for stable tumor-associated peptide presentation, thereby advancing the development of next-generation cancer vaccines.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model

  • Garcia León, Annabel|||0000-0003-3007-9306
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Rueda, Ariana|||0000-0001-7588-9279
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sierra, Jorge|||0000-0002-7966-0356
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Acute myeloid leukemia (AML) presents major clinical challenges due to chemoresistance and high relapse rates, primarily driven by therapy-resistant leukemic stem cells (LSCs) within the bone marrow. To address this issue, we developed T22-HSNBT-H6-MMAE, a novel humanized nanoconjugate designed to target CXCR4 cells while delivering the cytotoxic payload monomethyl auristatin E (MMAE). CXCR4 signaling pathway plays a critical role in LSC survival by preserving stem-like properties and activating protective mechanisms that promote treatment resistance. Moreover, CXCR4 is overexpressed in approximately 50 % of AML patients and is associated with poor prognosis and high relapse rates. We evaluated the therapeutic potential of T22-HSNBT-H6-MMAE using in vitro assays with AML cell lines and primary patient samples, as well as in vivo studies in a disseminated AML mouse model. Our results demonstrated that T22-HSNBT-H6-MMAE exerts a CXCR4-dependent cytotoxic effect through mitotic catastrophe and apoptosis induction in CXCR4 AML cell lines. In vivo evaluation in a disseminated CXCR4 AML mouse model showed potent antineoplastic activity, with complete suppression of leukemic dissemination and significantly prolonged survival, all without systemic toxicity. Notably, the nanoconjugate remained effective even in models with extensive bone marrow involvement and exhibited activity against diverse patient-derived CXCR4 AML blasts, while sparing healthy donor bone marrow and peripheral blood mononuclear cells (PBMCs) from significant toxicity. Collectively, these findings highlight T22-HSNBT-H6-MMAE as a promising therapeutic candidate for a broad range of AML patients, offering selective antineoplastic activity against CXCR4 leukemic cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparative mortality of dominant Staphylococcus aureus lineages in human bacteremia and animal infection models

  • Sánchez-Osuna, Miquel|||0000-0001-5267-4814
  • Bravo Bravo, Marc|||0000-0002-3173-2242
  • Cañas, María Alexandra|||0000-0002-0521-7204
  • Gómez, Andromeda-Celeste|||0000-0002-0075-6903
  • Gómez-Sánchez, Inmaculada|||0000-0002-4255-0882
  • Miró, José M.|||0000-0001-8057-7755
  • Gibert, Isidre|||0000-0003-1442-2258
  • Gasch, Oriol|||0000-0001-8518-458X
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Yero, Daniel|||0000-0002-6234-4082
  • Pich, Oscar Q.|||0000-0003-3561-630X
Staphylococcus aureus is a major human pathogen responsible for severe infections, including infective endocarditis. While host factors influencing disease outcome are well characterized, lineage-specific virulence mechanisms remain poorly defined. Herein, we investigated eighty-nine bacteremic S. aureus isolates from nine globally distributed lineages using Galleria mellonella and rabbit infection models, alongside phenotypic and transcriptomic analyses. Despite marked genotypic and phenotypic heterogeneity, mortality in G. mellonella varied significantly between lineages and correlated with hemolytic activity. ST398 isolates demonstrated heightened larval virulence linked to increased α- and δ-hemolysin production, whereas CC30 strains exhibited reduced growth, biofilm formation and infectivity. The ST398 agrC mutant Sau7 displayed a distinct phenotype, with elevated biofilm production but attenuated larval virulence. However, in the rabbit endocarditis model, Sau7 exhibited mortality rates similar to other ST398 isolates and was associated with larger vegetations and higher bacterial burdens, underscoring the role of the agr system in colonization and biofilm development. Transcriptomic profiling highlighted quorum-sensing pathways and hemolysin expression as key drivers of virulence in ST398 strains. Our findings reveal clear lineage-specific differences in S. aureus pathogenicity and demonstrate that virulence is context dependent, varying across infection models. These results emphasize the importance of using complementary in vivo systems to capture the multifaceted nature of S. aureus disease potential and to better predict infection outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engineered Mycoplasma pneumoniae targeting dual-species bacterial biofilms, a novel strategy against infections

  • Mazzolini, Rocco|||0000-0003-3249-8387
  • Garrido, Victoria|||0000-0002-2497-7188
  • Gómez, Andromeda-Celeste|||0000-0002-0075-6903
  • Collantes, María
  • Grilló, María Jesús|||0000-0002-1819-0186
  • Piñero-Lambea, Carlos|||0000-0002-5263-3702
  • Gibert, Isidre|||0000-0003-1442-2258
  • Yero, Daniel|||0000-0002-6234-4082
  • Lluch-Senar, Maria|||0000-0001-7568-4353
Antimicrobial resistance is a major global health threat, potentially causing 8.22 million deaths annually by 2050. Polymicrobial biofilms significantly contribute to this crisis, leading to treatment failure, especially in chronic airway infections caused by Staphylococcus aureus and Pseudomonas aeruginosa, common in ventilator-associated pneumonia and cystic fibrosis. To address this, we engineered an attenuated Mycoplasma pneumoniae strain, CV8_HAD, to secrete biofilm-disrupting enzymes (PelAh, PslGh, A1-II' and Dispersin B). CV8_HAD showed strong in vitro activity against single and mixed-species biofilms of S. aureus and P. aeruginosa, and demonstrated in vivo efficacy against S. aureus biofilms in mice and mixed infections in Galleria mellonella larvae. This study establishes engineered M. pneumoniae as a promising therapeutic strategy for tackling microbial biofilms and highlights the potential of G. mellonella larvae models as an alternative to mouse models in advancing research on biofilm-targeting interventions.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Recombinant protein drugs: a 2025 update

  • Lopez Laguna, Hector
  • Parladé Molist, Eloi
  • Teixeira De Pinho Favaro, Marianna
  • Palacín Ramos, Carlos
  • Voltà Durán, Eric
  • Ferrer Miralles, Neus
  • Corchero Nieto, Jose Luis
  • Rodríguez Rodríguez, Rosalía
  • Vázquez Gómez, Esther
  • Unzueta Elorza, Ugutz
  • Villaverde Corrales, Antonio
Over the past decade, recombinant protein therapeutics have moved from conventional biologics toward highly engineered, multifunctional versions. Enabled by innovations in synthetic biology, host cell engineering, and bioprocess optimization, proteins are increasingly viewed not only as drugs for replacement therapies but also as fully versatile platforms in innovative therapeutic approaches aiming at functional reprogramming. Advances in host systems, from optimized microbial strains to mammalian and plant-based platforms, have expanded the range of proteins that can be produced with high fidelity, scalability, and safety. In parallel, modular protein engineering has delivered next-generation formats, including bispecific antibodies, nanobodies, fusion proteins, and self-assembling biomaterials, broadening therapeutic applications across oncology, inflammation, metabolic disorders, and beyond. At the same time, regulatory frameworks are adapting to support accelerated approval of personalized and complex biologics, while decentralized and flexible manufacturing models begin to emerge. This review provides a 2025 update on the field of recombinant protein drugs, integrating advances in production platforms, protein engineering, and regulatory science, and outlining how these technologies are shaping the next generation of biologics., Open Access funding provided by CERCA through the CRUE-CSIC agreement with Springer Nature. We appreciate the support for our projects about the production of recombinant protein drugs, that have been mainly funded by AGAUR (grant number 2021SGR00092) and by CIBER-Consorcio Centro de Investigación Biomédica en Red- (grant number CB06/01/0014), through the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms

  • Parladé Molist, Eloi
  • Favaro, Marianna TP
  • Chellou Bakkali, Sara
  • Voltà Durán, Eric
  • Lopez Laguna, Hector
  • Villaverde, Antoni
  • Vázquez Gómez, Esther
Subunit vaccines are often limited by poor solubility and structural instability, affecting their ability to induce strong immune responses. Scaffold-based antigen display offers a promising solution, but translating designs into stable, scalable proteins remains challenging. Here, we present a pipeline for selecting and inserting tumor-derived peptide sequences into ß-barrel protein frameworks, using both GFP and the structurally similar G2 domain of the mouse nidogen. We validate the ASP173 loop in GFP as an effective insertion site, accommodating a double-peptide construct, as well as two distinct single peptides, without compromising folding or fluorescence. We further show that this design logic extends to the mouse nidogen G2 domain, which we employ as a host-native scaffold to carry the inserted epitope. The resulting constructs retain structural integrity and thermal stability, supporting their use in preclinical models and facilitating future applications in human health. This work establishes a modular, mammalian-compatible platform for stable tumor-associated peptide presentation, thereby advancing the development of next-generation cancer vaccines., The study was mainly funded by the Agencia Española de Investigación (AEI) through the project PID2022-136845OB-10/AEI/10.13039/501100011033 to E.V. and by AGAUR through the project SGR 2021 00092 to A.V. We would like to thank the ISCIII for funding CIBER-BBN (CB06/01/0014 and NANOREMOTE) and the Ministry of Science for funding the ICTS Platform Nanbiosis. The production of the fusion proteins was assisted, in part, by the Protein Production (PPP) Unit of the Platform Nanbiosis of the CIBER-BBN/IBB. Molecular graphics were performed with UCSF Chimera and ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from the National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. ESI-TOF and ICP-MS experiments were performed at Servei d'Anàlisi Química (SAQ) in Universitat Autònoma de Barcelona (UAB). Fluorimetry experiments were performed at Servei de Genòmica i Espectroscòpia de Biomolècules (SGiEB) in UAB. Electron microscopy was performed at the Servei de Microscòpia i Difracció de Raigs X (UAB). MALDI-TOF experiments were performed at Unitat d'Espectrometria de Masses de Caracterització Molecular CCiTUB in Universitat de Barcelona (UB)., Peer Reviewed, Postprint (published version)
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant Proteins for Assembling as Nano- and Micro-Scale Materials for Drug Delivery, A Host Comparative Overview

  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Márquez-Martínez, Merce|||0000-0003-2157-5850
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferreira, Luis|||0000-0002-4883-1693
  • Vázquez, Esther|||0000-0003-1052-0424
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Parladé, Eloi|||0000-0001-5750-550X
By following simple protein engineering steps, recombinant proteins with promising applications in the field of drug delivery can be assembled in the form of functional materials of increasing complexity, either as nanoparticles or nanoparticle-leaking secretory microparticles. Among the suitable strategies for protein assembly, the use of histidine-rich tags in combination with coordinating divalent cations allows the construction of both categories of material out of pure polypeptide samples. Such molecular crosslinking results in chemically homogeneous protein particles with a defined composition, a fact that offers soft regulatory routes towards clinical applications for nanostructured protein-only drugs or for protein-based drug vehicles. Successes in the fabrication and final performance of these materials are expected, irrespective of the protein source. However, this fact has not yet been fully explored and confirmed. By taking the antigenic RBD domain of the SARS-CoV-2 spike glycoprotein as a model building block, we investigated the production of nanoparticles and secretory microparticles out of the versions of recombinant RBD produced by bacteria (Escherichia coli), insect cells (Sf9), and two different mammalian cell lines (namely HEK 293F and Expi293F). Although both functional nanoparticles and secretory microparticles were effectively generated in all cases, the technological and biological idiosyncrasy of each type of cell factory impacted the biophysical properties of the products. Therefore, the selection of a protein biofabrication platform is not irrelevant but instead is a significant factor in the upstream pipeline of protein assembly into supramolecular, complex, and functional materials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticles

  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Serna, Naroa|||0000-0001-5682-8198
  • Imedio, Laura
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Two human proteins involved in the inflammatory cell death, namely Gasdermin D (GSDMD) and the Mixed Lineage Kinase Domain-Like (MLKL) protein have been engineered to accommodate an efficient ligand of the tumoral cell marker CXCR4, and a set of additional peptide agents that allow their spontaneous self-assembling. Upon production in bacterial cells and further purification, both proteins organized as stable nanoparticles of 46 and 54 nm respectively, that show, in this form, a moderate but dose-dependent cytotoxicity in cell culture. In vivo, and when administered in mouse models of colorectal cancer through repeated doses, the nanoscale forms of tumor-targeted GSDMD and, at a lesser extent, of MLKL promoted CD8+ and CD20+ lymphocyte infiltration in the tumor and an important reduction of tumor size, in absence of systemic toxicity. The potential of these novel pharmacological agents as anticancer drugs is discussed in the context of synergistic approaches to more effective cancer treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins

  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Ferreira, Luís C.S.
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Among bio-inspired protein materials, secretory protein microparticles are of clinical interest as self-contained, slow protein delivery platforms that mimic secretory granules of the human endocrine system, in which the protein is both the drug and the scaffold. Upon subcutaneous injection, their progressive disintegration results in the sustained release of the building block polypeptides, which reach the bloodstream for systemic distribution and subsequent biological effects. Such entities are easily fabricated in vitro by Zn-assisted cross-molecular coordination of histidine residues. Using cationic Zn for the assembly of selected pure protein species and in the absence of any heterologous holding material, these granules are expected to be nontoxic and therefore adequate for different clinical uses. However, such presumed biosafety has not been so far confirmed and the potential protein dosage threshold not probed yet. By selecting the receptor binding domain (RBD) from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein as a model protein and using a mouse lab model, we have explored the toxicity of RBD-made secretory granules at increasing doses up to ∼100 mg/kg of animal weight. By monitoring body weight and biochemical blood markers and through the histological scrutiny of main tissues and organs, we have not observed systemic toxicity. Otherwise, the bioavailability of the material was demonstrated by the induction of specific antibody responses. The presented data confirm the intrinsic biosafety of artificial secretory granules made by recombinant proteins and prompt their further clinical development as self-contained and dynamic protein reservoirs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High-precision targeting and destruction of cancer-associated PDGFR-β+ stromal fibroblasts through self-assembling, protein-only nanoparticles

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Serna, Naroa|||0000-0001-5682-8198
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
The need for more effective and precision medicines for cancer has pushed the exploration of new materials appropriate for drug delivery and imaging, and alternative receptors for targeting. Among the most promising strategies, finding suitable cell surface receptors and targeting agents for cancer-associated platelet derived growth factor receptor β (PDGFR-β)+ stromal fibroblasts is highly appealing. As a neglected target, this cell type mechanically and biologically supports the growth, progression, and infiltration of solid tumors in non-small cell lung, breast, pancreatic, and colorectal cancers. We have developed a family of PDGFR-β-targeted nanoparticles based on biofabricated, self-assembling proteins, upon hierarchical and iterative selective processes starting from four initial candidates. The modular protein PDGFD-GFP-H6 is well produced in recombinant bacteria, resulting in structurally robust oligomeric particles that selectively penetrates into PDGFR-β+ stromal fibroblasts in a dose-dependent manner, by means of the PDGFR-β ligand PDGFD. Upon in vivo administration, these GFP-carrying protein nanoparticles precisely accumulate in tumor tissues and enlighten them for IVIS observation. When GFP is replaced by a microbial toxin, selective tumor tissue destruction is observed associated with a significant reduction in tumor volume growth. The presented data validate the PDGFR-β/PDGFD pair as a promising toolbox for targeted drug delivery in the tumor microenvironment and oligomeric protein nanoparticles as a powerful instrument to mediate highly selective biosafe targeting in cancer through non-cancer cells. Statement of significance: We have developed a transversal platform for nanoparticle-based drug delivery into cancer-associated fibroblasts. This is based on the engineered modular protein PDGFD-GFP-H6 that spontaneously self-assemble and selectively penetrates into PDGFR-β+ stromal fibroblasts in a dose-dependent manner, by means of the PDGFR-β ligand PDGFD. In vivo, these protein nanoparticles accumulate in tumor and when incorporating a microbial toxin, they destroy tumor tissues with a significant reduction in tumor volume, in absence of side toxicities. The data presented here validate the PDGFR-β/PDGFD pair as a fully versatile toolbox for targeted drug delivery in the tumor microenvironment intended as a synergistic treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A high-throughput microtiter plate screening assay to quantify and differentiate species in dual-species biofilms

  • Campo Pérez, Víctor|||0000-0003-3161-9984
  • Alcàcer-Almansa, Júlia|||0000-0002-8688-3128
  • Julián, Esther|||0000-0002-6558-3978
  • Torrents, Eduard|||0000-0002-3010-1609
Pathogenic bacteria form biofilms during infection, and polymicrobial biofilms are the most frequent manifestation. Biofilm attachment, maturation, and/or antibiotic sensitivity are mainly evaluated with microtiter plate assays, in which bacteria are stained to enable the quantification of the biomass by optical absorbance or fluorescence emission. However, using these methods to distinguish different species in dual-species or polymicrobial biofilms is currently impossible. Colony-forming unit counts from homogenized dual-species biofilms on selective agar medium allow species differentiation but are time-consuming for a high-throughput screening. Thus, reliable, feasible, and fast methods are urgently needed to study the behavior of polymicrobial and dual-species communities. This study shows that Pseudomonas aeruginosa and Burkholderia cenocepacia strains expressing specific fluorescent or bioluminescent proteins permit the more efficient study of dual-species biofilms compared to other methods that rely on measuring the total biomass. Combining fluorescence and bioluminescence measurements allows an independent analysis of the different microbial species within the biofilm, indicating the degree of presence of each one over time during a dual-species biofilm growth. The quantitative strategies developed in this work are reproducible and recommended for dual-species biofilm studies with high-throughput microtiter plate approaches using strains that can constitutively express fluorescent or bioluminescent proteins.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Protein features instruct the secretion dynamics from metal-supported synthetic amyloids

  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Hexahistidine-tagged proteins can be clustered by divalent cations into self-containing, dynamic protein depots at the microscale, which under physiological conditions leak functional protein. While such protein granules show promise in clinics as time-sustained drug delivery systems, little is known about how the nature of their components, that is, the protein and the particular cation used as cross-linker, impact on the disintegration of the material and on its secretory performance. By using four model proteins and four different cation formulations to control aggregation, we have here determined a moderate influence of the used cation and a potent impact of some protein properties on the release kinetics and on the final fraction of releasable protein. In particular, the electrostatic charge at the amino terminus and the instability and hydropathicity indexes determine the disintegration profile of the depot. These data offer clues for the fabrication of efficient and fully exploitable secretory granulesthat being biocompatible and chemically homogenous allow their tailored use as drug delivery platforms in biological systems.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhanced recombinant protein capture, purity and yield from crude bacterial cell extracts by N-Lauroylsarcosine-assisted affinity chromatography

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Background: Recombinant proteins cover a wide range of biomedical, biotechnological, and industrial needs. Although there are diverse available protocols for their purification from cell extracts or from culture media, many proteins of interest such as those containing cationic domains are difficult to purify, a fact that results in low yields of the final functional product. Unfortunately, this issue prevents the further development and industrial or clinical application of these otherwise interesting products. Results: Aiming at improving the purification of such difficult proteins, a novel procedure has been developed based on supplementing crude cell extracts with non-denaturing concentrations of the anionic detergent N-Lauroylsarcosine. The incorporation of this simple step in the downstream pipeline results in a substantial improvement of the protein capture by affinity chromatography, an increase of protein purity and an enhancement of the overall process yield, being the detergent not detectable in the final product. Conclusion: By taking this approach, which represents a smart repurposing of N-Lauroylsarcosine applied to protein downstream, the biological activity of the protein is not affected. Being technologically simple, the N-Lauroylsarcosine-assisted protein purification might represent a critical improvement in recombinant protein production with wide applicability, thus smothering the incorporation of promising proteins into the protein market.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Endosomal escape for cell-targeted proteins. Going out after going in

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Serna, Naroa|||0000-0001-5682-8198
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Protein-based nanocarriers are versatile and biocompatible drug delivery systems. They are of particular interest in nanomedicine as they can recruit multiple functions in a single modular polypeptide. Many cell-targeting peptides or protein domains can promote cell uptake when included in these nanoparticles through receptor-mediated endocytosis. In that way, targeting drugs to specific cell receptors allows a selective intracellular delivery process, avoiding potential side effects of the payload. However, once internalized, the endo-lysosomal route taken by the engulfed material usually results in full degradation, preventing their adequate subcellular localization, bioavailability and subsequent therapeutic effect. Thus, entrapment into endo-lysosomes is a main bottleneck in the efficacy of protein-drug nanomedicines. Promoting endosomal escape and preventing lysosomal degradation would make this therapeutic approach clinically plausible. In this review, we discuss the mechanisms intended to evade lysosomal degradation of proteins, with the most relevant examples and associated strategies, and the methods available to measure that effect. In addition, based on the increasing catalogue of peptide domains tailored to face this challenge as components of protein nanocarriers, we emphasize how their particular mechanisms of action can potentially alter the functionality of accompanying protein materials, especially in terms of targeting and specificity in the delivery process.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synthesis and evaluation of aromatic BDSF bioisosteres on biofilm formation and colistin sensitivity in pathogenic bacteria

  • Gómez, Andromeda-Celeste|||0000-0002-0075-6903
  • Horgan, Conor
  • Yero, Daniel|||0000-0002-6234-4082
  • Bravo Bravo, Marc|||0000-0002-3173-2242
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • O'Driscoll, Michelle
  • Gibert, Isidre|||0000-0003-1442-2258
  • O'Sullivan, Timothy|||0000-0001-6649-331X
The diffusible signal factor family (DSF) of molecules play an important role in regulating intercellular communication, or quorum sensing, in several disease-causing bacteria. These messenger molecules, which are comprised of cis-unsaturated fatty acids, are involved in the regulation of biofilm formation, antibiotic tolerance, virulence and the control of bacterial resistance. We have previously demonstrated how olefinic N-acyl sulfonamide bioisosteric analogues of diffusible signal factor can reduce biofilm formation or enhance antibiotic sensitivity in a number of bacterial strains. This work describes the design and synthesis of a second generation of aromatic N-acyl sulfonamide bioisosteres. The impact of these compounds on biofilm production in Acinetobacter baumannii, Escherichia coli, Burkholderia multivorans, Burkholderia cepacia, Burkholderia cenocepacia, Pseudomonas aeruginosa and Stenotrophomonas maltophilia is evaluated, in addition to their effects on antibiotic tolerance. The ability of these molecules to increase survival rates on co-administration with colistin is also investigated using the Galleria infection model.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs)

  • Rueda, Ariana|||0000-0001-7588-9279
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Parladé, Eloi|||0000-0001-5750-550X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Paez, David|||0000-0002-5596-6588
  • Aviñó, Ana|||0000-0003-3047-738X
  • Eritja, Ramon|||0000-0001-5383-9334
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The development of a new generation of non-antibody protein drug delivery systems requires site-directed conjugation strategies to produce homogeneous, reproducible and scalable nanomedicines. For that, the genetic addition of cysteine residues into solvent-exposed positions allows the thiol-mediated cysteine coupling of therapeutic drugs into protein-based nanocarriers. However, the high reactivity of unpaired cysteine residues usually reduces protein stability, consequently imposing the use of more methodologically demanding purification procedures. This is especially relevant for disulfide-containing nanocarriers, as previously observed in THIOMABs. Moreover, although many protein scaffolds and targeting ligands are also rich in disulfide bridges, the use of these methodologies over emerging non-antibody carrier proteins has been completely neglected. Here, we report the development of a simple and straightforward procedure for a one-step production and site-directed cysteine conjugation of disulfide-containing non-antibody thiolated carrier proteins (THIOCAPs). This method is validated in a fluorescent C-X-C chemokine receptor 4 (CXCR4)-targeted multivalent nano-carrier containing two intramolecular disulfide bridges and one reactive cysteine residue strategically placed into a solvent-exposed position (THIO-T22-GFP-H6) for drug conjugation and in a humanized alternative intended for clinical applications (T22-HSNBT-H6). Thus, we produce very stable, homogeneous and fully functional antitumoral nanoconjugates (THIO-T22-GFP-H6-MMAE and T22-HSNBT-H6-MMAE) that selectively eliminate target cancer cells via CXCR4-receptor. Altogether, the developed methodology appears as a powerful tool for the rational engineering of emerging non-antibody, cell-targeted protein nanocarriers that contain disulfide bridges together with a solvent-exposed reactive cysteine (THIOCAP). This should pave the way for the development of a new generation of stable, homogeneous and efficient nanomedicines.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficient Delivery of Antimicrobial Peptides in an Innovative, Slow-Release Pharmacological Formulation

  • Serna, Naroa|||0000-0001-5682-8198
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Aceituno Abarzúa, Patricia|||0000-0002-6015-3274
  • Rojas Peña, Mauricio|||0000-0002-2373-1792
  • Parladé, Eloi|||0000-0001-5750-550X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Di Somma, Angela|||0000-0003-4916-7875
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Livieri, Andrea L.
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Villaverde, Antonio|||0000-0002-2615-4521
Both nanostructure and multivalency enhance the biological activities of antimicrobial peptides (AMPs), whose mechanism of action is cooperative. In addition, the efficacy of a particular AMP should benefit from a steady concentration at the local place of action and, therefore, from a slow release after a dynamic repository. In the context of emerging multi-resistant bacterial infections and the urgent need for novel and effective antimicrobial drugs, we tested these concepts through the engineering of four AMPs into supramolecular complexes as pharmacological entities. For that purpose, GWH1, T22, Pt5, and PaD, produced as GFP or human nidogen-based His-tagged fusion proteins, were engineered as self-assembling oligomeric nanoparticles ranging from 10 to 70 nm and further packaged into nanoparticle-leaking submicron granules. Since these materials slowly release functional nanoparticles during their time-sustained unpacking, they are suitable for use as drug depots in vivo. In this context, a particular AMP version (GWH1-NIDO-H6) was selected for in vivo validation in a zebrafish model of a complex bacterial infection. The GWH1-NIDO-H6-secreting protein granules are protective in zebrafish against infection by the multi-resistant bacterium Stenotrophomonas maltophilia, proving the potential of innovative formulations based on nanostructured and slowly released recombinant AMPs in the fight against bacterial infections.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Improved biosensing of Legionella by integrating filtration and immunomagnetic separation of the bacteria retained in filters

  • Mesas Gómez, Melania|||0000-0002-3297-1077
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • de Araújo, Bárbara Camila
  • Boldrin Zanoni, Maria Valnice|||0000-0002-2296-1393
  • Julián, Esther|||0000-0002-6558-3978
  • Domínguez, José|||0000-0001-7888-0309
  • Pividori, María Isabel|||0000-0002-5266-7873
A novel approach is presented that combines filtration and the direct immunomagnetic separation of the retained bacteria Legionella in filters, for further electrochemical immunosensing. This strategy allows for the separation and preconcentration of the water-borne pathogen from high-volume samples, up to 1000 mL. The limit of detection of the electrochemical immunosensor resulted in 100 CFU mL-1 and improved up to 0.1 CFU mL-1 when the preconcentration strategy was applied in 1 L of sample (103-fold improvement). Remarkably, the immunosensor achieves the limit of detection in less than 2.5 h and simplified the analytical procedure. This represents the lowest concentration reported to date for electrochemical immunosensing of Legionella cells without the need for pre-enrichment or DNA amplification. Furthermore, the study successfully demonstrates the extraction of bacteria retained on different filtering materials using immunomagnetic separation, highlighting the high efficiency of the magnetic particles to pull out the bacteria directly from solid materials. This promising feature expands the applicability of the method beyond water systems for detecting bacteria retained in air filters of air conditioning units by directly performing the immunomagnetic separation in the filters.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mycobacterium detection method combining filtration, immunomagnetic separation, and electrochemical readout in a portable biosensing device

  • Mesas Gómez, Melania|||0000-0002-3297-1077
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • de Araújo, Bárbara Camila
  • Pallarès-Rusiñol, Arnau|||0000-0001-9990-148X
  • Ferrer-Dalmau, Jofre|||0000-0002-7415-6222
  • Boldrin Zanoni, Maria Valnice|||0000-0002-2296-1393
  • Domínguez, José|||0000-0001-7888-0309
  • Julián, Esther|||0000-0002-6558-3978
  • Pividori, María Isabel|||0000-0002-5266-7873
This study addresses a straightforward and highly sensitive approach for detecting Mycobacterium fortuitum. The method involves a combination of filtration and direct immunomagnetic separation to isolate the bacteria retained on filters for further electrochemical magneto immunosensing in a handheld device. Unlike conventional methods involving pre-enrichment by culturing, this approach employs a simplified preconcentration technique, which includes filtration of large water samples, up to 100 mL, followed by a one-step process of immunomagnetic separation and labeling. After a 60-min, during which the filter with the retained bacteria and all the reagents (including modified magnetic particles and enzymatic conjugates) are incubated, the resulting product is directly drop into a cartridge, capable of performing magnetic actuation and washing. The electrochemical readout is carried out on a portable battery-operated device within 30 seconds. Remarkably, the immunosensor demonstrates an outstanding limit of detection of 5 CFU mL-1 in hemodialysis water processing 100 mL of sample. This achievement is remarkable considering the short and simplified analytical procedure, compared to the traditional isolation and culturing of mycobacteria, which typically takes 2 weeks.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez, Merce
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Ferreira, Luis|||0000-0002-4883-1693
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Parladé, Eloi|||0000-0001-5750-550X
  • Villaverde, Antonio|||0000-0002-2615-4521
The development of new and more efficient vaccination approaches is a constant need, due to the pressure of historical and emerging infectious diseases and the limited efficacy and universality of the current vaccination technologies. Peptides and recombinant proteins have been explored for decades as subunit vaccines for bacterial and viral infections, presented either as soluble protein species or as virus-like assemblies. Recently, synthetic secretory protein-only microscale granules have been developed as dynamic depots for sustained protein release. They are based on the reversible coordination between ionic Zn and histidine residues, which promotes a fast formation of granular particles in vitro out of soluble protein and a slow release of such building block protein in vivo through the physiological chelation of the metal. Such an endocrine-like platform represents a new drug delivery system fully validated in oncology by which soluble and functional protein drugs are progressively released from the granules and made available for antitumor activities upon subcutaneous administration. By exploring such an approach for immunization here, microparticles made of a recombinant form of the receptor binding domain (RBD) of SARS-CoV-2 were tested as an antigen delivery system for induction of antibody responses against the virus upon administration of the material in the absence of added adjuvants. Also, the comparison between protein materials produced in bacterial, mammalian, or insect cell factories has demonstrated a moderate impact of protein glycosylation on the final immunological performance of the system. Therefore, we propose the consideration of synthetic protein secretory granules as a new sustainable immunization platform based on fully manageable, self-organized, and self-formulated immunogens, aimed at reducing the dosage, costs, and complexity of vaccination regimens.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanoparticle-Based Secretory Granules Induce a Specific and Long-Lasting Immune Response through Prolonged Antigen Release

  • Bosch Camós, Laia|||0000-0001-6245-4284
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Argilaguet, Jordi|||0000-0001-5924-2774
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Rodriguez, Fernando|||0000-0001-7361-8408
  • Vázquez, Esther|||0000-0003-1052-0424
Developing prolonged antigen delivery systems that mimic long-term exposure to pathogens appears as a promising but still poorly explored approach to reach durable immunities. In this study, we have used a simple technology by which His-tagged proteins can be assembled, assisted by divalent cations, as supramolecular complexes with progressive complexity, namely protein-only nanoparticles and microparticles. Microparticles produced out of nanoparticles are biomimetics of secretory granules from the mammalian hormonal system. Upon subcutaneous administration, they slowly disintegrate, acting as an endocrine-like secretory system and rendering the building block nanoparticles progressively bioavailable. The performance of such materials, previously validated for drug delivery in oncology, has been tested here regarding the potential for time-prolonged antigen release. This has been completed by taking, as a building block, a nanostructured version of p30, a main structural immunogen from the African swine fever virus (ASFV). By challenging the system in both mice and pigs, we have observed unusually potent pro-inflammatory activity in porcine macrophages, and long-lasting humoral and cellular responses in vivo, which might overcome the need for an adjuvant. The robustness of both innate and adaptive responses tag, for the first time, these dynamic depot materials as a novel and valuable instrument with transversal applicability in immune stimulation and vaccinology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evaluating smartphone-based optical readouts for immunoassays in human and veterinary healthcare, A comparative study

  • Mesas Gómez, Melania|||0000-0002-3297-1077
  • Julián, Esther|||0000-0002-6558-3978
  • Armengou Ruiz, Lara|||0000-0003-4715-7323
  • Pividori, María Isabel|||0000-0002-5266-7873
Recent advances have significantly enhanced the use of smartphone devices for medical diagnostics. This study uses high-resolution cameras in mobile devices to capture and process bioassay images, enabling the quantification of diverse biomarkers across a range of diagnostic tests conducted on 96-well microplates. The study evaluates the effectiveness of this technology through protein quantification techniques and immunoassays that generate colorimetric responses at specific wavelengths. It includes the assessment of bicinchoninic acid and Bradford protein quantification methods, alongside a conventional immunoassay for detecting mare antibodies in colostrum to monitor foal immunodeficiencies. Further application involves the readout of magneto-actuated immunoassays aimed at quantifying bacteria. The results obtained from benchtop spectrophotometry at 595, 562, and 450 nm are compared with those acquired using a smartphone, which identified color intensities in shades of blue, purple, and yellow. This comparison yields promising correlations for the samples tested, suggesting a high degree of accuracy in the smartphone capability to analyze bioassay outcomes. The analysis via smartphone is facilitated by a specific app, which processes the images captured by the phone camera to quantify color intensities corresponding to different biomarker concentrations. Detection limits of 12.3 and 22.8 μg mL for the bicinchoninic acid assay and 36.7 and 45.4 μg mL for the Bradford are obtained for protein quantification using the spectrophotometer and the smartphone app, respectively. For mare's antibodies in colostrum, the values are 1.14 and 1.72 ng mL, while the detection of E. coli is performed at 2.0 x 10 and 2.9 × 10 CFU mL, respectively. This approach offers further advantages, including wide availability, cost-effectiveness, portability, compared to traditional and expensive benchtop instruments.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles

  • Parladé, Eloi|||0000-0001-5750-550X
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Surface-exposed calreticulin (CRT) serves as a crucial cell damage-associated molecular pattern for immunogenic apoptosis, by generating an "eat me" signal to macrophages. Aiming at precision immunotherapies we intended to artificially label tumoral cells in vivo with a recombinant CRT, in a targeted way. For that, we have constructed a CRT fusion protein intended to surface attach CXCR4 cancer cells, to stimulate their immunological destruction. As a targeting ligand of the CRT construct and to drive its specific cell adhesion, we used the peptide V1, a derivative of the vMIP-II cytokine and an antagonist of CXCR4. The modular protein tends to self-assemble as regular 16 nm nanoparticles, assisted by ionic Zn. Through both in vivo and in vitro experiments, we have determined that CRT itself confers cell targeting capabilities to the construct overcoming those of V1, that are only moderate. In particular, CRT binds HeLa cells in absence of further internalization, by a route fully independent of CXCR4. Furthermore, by cytometry in THP-1 cells, we observed that the binding of the protein is preferential for dead cells over live cells, a fact that cannot be associated to a mere artefactual adsorption. These data are discussed in the context of the oligomerizing properties of CRT and the potential clinical applicability of proteins and protein materials functionalized with this novel cell surface ligand.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lyophilization of biomimetic amyloids preserves their regulatable, endocrine-like functions for nanoparticle release

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
The secretory granules from the mammalian endocrine system are functional amyloids that act as dynamic depots to store and release protein hormones into the bloodstream. The controlled in vitro coordination between divalent cations and solvent-exposed histidine residues triggers reversible, cross-molecular interactions that result in granular protein aggregates with protein-leaking properties. While these synthetic particles are mechanically stable, they progressively disintegrate and release their protein building blocks, mimicking the performance of secretory granules. Envisaged as delivery systems for endocrine-like, time-sustained protein release, their clinical applicability should be supported by robust storage procedures, so far unset. Being lyophilization a desirable storage method for protein drugs, how this procedure could preserve the performance of clinically oriented functional amyloids is a neglected issue. We have here explored, tailored and validated lyophilization as an industrially and clinically friendly, fully scalable approach to the storage of functional amyloids aimed at secretion of protein-only nanoparticles. By doing so, protein-protein interactions in such materials have been characterized, and citrate identified as an efficient modulator of the temporal secretion profile, through which the sustainability of the leaking process can be finely regulated.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Mla system and its role in maintaining outer membrane barrier function in Stenotrophomonas maltophilia

  • Coves, Xavier|||0000-0002-8970-8907
  • Mamat, Uwe
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Huedo Moreno, Pol|||0000-0002-2933-0586
  • Bravo Bravo, Marc|||0000-0002-3173-2242
  • Gómez, Andromeda-Celeste|||0000-0002-0075-6903
  • Krohn, Ines
  • Streit, Wolfgang R.|||0000-0001-7617-7396
  • Schaible, Ulrich E.|||0000-0002-6638-7282
  • Gibert, Isidre|||0000-0003-1442-2258
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Yero, Daniel|||0000-0002-6234-4082
Stenotrophomonas maltophilia are ubiquitous Gram-negative bacteria found in both natural and clinical environments. It is a remarkably adaptable species capable of thriving in various environments, thanks to the plasticity of its genome and a diverse array of genes that encode a wide range of functions. Among these functions, one notable trait is its remarkable ability to resist various antimicrobial agents, primarily through mechanisms that regulate the diffusion across cell membranes. We have investigated the Mla ABC transport system of S. maltophilia, which in other Gram-negative bacteria is known to transport phospholipids across the periplasm and is involved in maintaining outer membrane homeostasis. First, we structurally and functionally characterized the periplasmic substrate-binding protein MlaC, which determines the specificity of this system. The predicted structure of the S. maltophilia MlaC protein revealed a hydrophobic cavity of sufficient size to accommodate the phospholipids commonly found in this species. Moreover, recombinant MlaC produced heterologously demonstrated the ability to bind phospholipids. Gene knockout experiments in S. maltophilia K279a revealed that the Mla system is involved in baseline resistance to antimicrobial and antibiofilm agents, especially those with divalent-cation chelating activity. Co-culture experiments with Pseudomonas aeruginosa also showed a significant contribution of this system to the cooperation between both species in the formation of polymicrobial biofilms. As suggested for other Gram-negative pathogenic microorganisms, this system emerges as an appealing target for potential combined antimicrobial therapies.